Company intelligence / Profile preview

Modulight Corporation

Ownership: Private
Employees: ~66
Development stage: Commercial

Overview

Modulight received FDA premarket approval (PMA) for its ML6710i laser device for treating wet age-related macular degeneration in January 2023. The company has multiple laser products on the market for various medical applications.

Therapeutic areas: OncologyOphthalmologyNeurology
Modalities: Laser-based therapiesOptogenetics
Industry: Therapeutic Medical Devices

Partnerships

Bausch + LombMultiple pharmaceutical companies (including one of the five largest pharmaceutical companies for lung cancer initiative)

Beyond the preview

Go deeper on Modulight Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modulight Corporation.

Explore the full profile